FIELD: biotechnology.
SUBSTANCE: described is a vaccine suitable for detecting an immunological response to African swine fever virus (ASFV). Vaccine contains an effective immunizing amount of a recombinant nucleic acid molecule containing an expression cassette encoding a polyepitope containing T-cell antigens from African swine fever virus proteins, wherein said T-cell antigens are separated by spacers, which contain signals for proteasome cleavage, and/or a viral particle containing said recombinant nucleic acid molecule, wherein said vaccine additionally contains a viral particle containing B-cell antigens of African swine fever virus and a veterinary acceptable excipient. Disclosed is a method for stimulating an immune response in a pig, involving administering a vaccine to a pig in an amount effective for inducing an immune response. Described is a method for preventing or reducing manifestations of infection and/or spread of African swine fever virus in pigs, involving administration of a vaccine. Disclosed is a set of viral particles comprising a virus particle comprising a recombinant nucleic acid molecule comprising an expression cassette encoding a polyepitope containing T-cell antigens from African swine fever virus proteins, wherein said T-cell antigens are separated by spacers which contain signals for proteasome cleavage; and one or more viral particles containing B-cell antigens of African swine fever virus, for use in a method of protecting swine from infection caused by African swine fever virus. Described is a set of components containing said vaccine for use in a method of protecting swine against infection caused by African swine fever virus.
EFFECT: invention extends the range of agents for protecting swine against infection caused by African swine fever virus.
20 cl, 3 dwg, 2 tbl, 2 ex
